scispace - formally typeset
Journal ArticleDOI

Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas.

Lawrence Hsu Lin, +12 more
- 06 Aug 2021 - 
- Vol. 34, Iss: 12, pp 2168-2174
Reads0
Chats0
TLDR
In this article, the authors compare the sensitivity, specificity, and accuracy of a plasma-based NGS assay to a solid-tumor based NGS, and conclude that tissue-NGS should be the preferred method for molecular testing of lung adenocarcinoma when tissue is available.
About: 
This article is published in Modern Pathology.The article was published on 2021-08-06. It has received 14 citations till now. The article focuses on the topics: Liquid biopsy & Gene mutation.

read more

Citations
More filters
Journal ArticleDOI

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives

Yan Peng, +3 more
- 18 Nov 2021 - 
TL;DR: In this article, the authors summarized the current knowledge of ctDNA and minimum residual disease (MRD) in solid tumors, focusing on the potential clinical applications and challenges, and evaluated the clinical utility of CtDNA analysis, such as recurrence risk assessment, monitoring response, and resistance mechanism analysis.
Journal ArticleDOI

Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review.

Maisam Makarem, +2 more
- 22 Oct 2021 - 
TL;DR: A review of the current and future applications of plasma-circulating tumor DNA (ctDNA) based assays in advanced solid malignancies, while highlighting some limitations in implementing this technology into clinical practice is presented in this paper.
Journal ArticleDOI

Single whole genome sequencing analysis blazes the trail for precision medicine

Giulia C Napoli, +2 more
- 06 Feb 2022 - 
TL;DR: A recent study observing a remarkably stable driver gene mutational profile among 250 biopsy pairs from 231 patients undergoing standard of care treatments during the biopsy interval suggests that the actionable metastatic cancer genome is relatively stable over time and that a single WGS provides a complete view of the treatment opportunities available to most metastaticcancer patients.
Journal ArticleDOI

Circulating Tumor DNA in Pediatric Cancer

Louise Doculara, +3 more
- 12 May 2022 - 
TL;DR: The current understanding of ctDNA as a disease monitoring biomarker in the context of pediatric malignancies is discussed, including the challenges associated with ct DNA detection in liquid biopsies, and the requirements for the standardization of cTDNA detection in pediatric cancers are outlined.
Journal ArticleDOI

Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC

Patrice Desmeules, +6 more
- 01 Jan 2023 - 
TL;DR: In this article , the authors evaluated the value of complementary circulating tumor DNA (ctDNA) NGS on tissue single-gene testing (SGT) for non-small cell lung cancer (NSCLC) management and plasma based next-generation sequencing (NGS) is increasingly characterized as a noninvasive alternative.
References
More filters
Journal ArticleDOI

The generalisation of student's problems when several different population variances are involved.

Welch Bl
- 01 Jan 1947 - 
Journal ArticleDOI

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Chetan Bettegowda, +69 more
- 19 Feb 2014 - 
TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.
Journal ArticleDOI

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Jean-Charles Soria, +23 more
- 11 Jan 2018 - 
TL;DR: Osimertinib showed efficacy superior to that of standard EGFR‐TKIs in the first‐line treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events.
Journal ArticleDOI

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

Benjamin Solomon, +14 more
- 03 Dec 2014 - 
TL;DR: Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC and was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life.
Journal ArticleDOI

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Aaron M. Newman, +13 more
- 06 Apr 2014 - 
TL;DR: It is envisioned that CAPP-Seq could be routinely applied clinically to detect and monitor diverse malignancies, thus facilitating personalized cancer therapy.
Related Papers (5)

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers

Joshua K. Sabari, +38 more
- 01 Jun 2019 - 

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

Cloud P. Paweletz, +12 more
- 15 Feb 2016 - 

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.

Aaron C. Tan, +25 more
- 01 Jan 2020 - 

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

Bob T. Li, +30 more
- 01 Apr 2019 - 

Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non–Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 Samples

Antoine Legras, +20 more
- 01 Jul 2018 -